Meralys

Xylometazoline Hydrochloride, the active ingredient in Meralys, is an alpha-adrenergic agonist presented as a nasal spray for nasal use. It relieves nasal congestion associated with the common cold, sinusitis, and allergic rhinitis, providing rapid improvement in breathing.\n\nGNH India supplies Meralys as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Xylometazoline Hydrochloride is a nasal decongestant that reduces swelling of nasal mucosa in upper‑respiratory conditions.\n\n- Common cold: alleviates nasal congestion and improves airflow.\n- Sinusitis: reduces mucosal swelling to ease sinus drainage.\n- Allergic rhinitis: diminishes nasal blockage caused by allergic inflammation.

Xylometazoline Hydrochloride may cause local and systemic adverse reactions, most of which are mild and reversible.\n\nCommon Side Effects:\n- Nasal burning or stinging: mild irritation at the application site.\n- Sneezing: transient reflex response.\n- Dry nasal mucosa: dryness or crusting.\n- Headache: mild headache.\n\nSerious or Rare Side Effects:\n- Nasal septum perforation: rare tissue damage with prolonged use.\n- Hypertension: elevated blood pressure in susceptible individuals.\n- Rebound congestion: worsening nasal blockage after extended use.\n- Allergic reaction: rash, itching, or swelling.

When using Meralys, consider the following safety measures.\n\n- Duration of use: limit to 3‑5 days to avoid rebound congestion.\n- Age restrictions: not recommended for children under 6 years without medical advice.\n- Pregnancy and lactation: consult a healthcare professional before use.\n- Existing cardiovascular disease: use with caution due to possible systemic vasoconstriction.\n- Concurrent nasal sprays: avoid using other decongestant sprays simultaneously.\n- Store at room temperature: keep in original container, protect from moisture and direct sunlight.

Xylometazoline Hydrochloride can interact with certain medications, affecting its safety profile.\n\nMajor Interactions (Avoid):\n- Monoamine oxidase inhibitors (MAOIs): risk of excessive vasoconstriction.\n- Sympathomimetic drugs: additive hypertensive effect.\n\nModerate Interactions (Monitor Closely):\n- Antihypertensive agents: may reduce blood pressure control.\n- Nasal corticosteroids: monitor for increased local irritation.\n- Other nasal decongestants: risk of cumulative vasoconstriction.